AVDL - Jazz Pharma starting to clear away legal overhang Evercore ISI says

Jazz Pharmaceuticals (JAZZ) appears to be starting to clear away a legal overhang with Xyrem lawsuits, according to Evercore ISI.There are a number of class action lawsuits on Xyrem that could fasten the generic entry to as early as 2023 from 2026, according to Evercore analyst Umer Raffat.Evercore has been studying the lawsuits and it appears that JAZZ attorney have "effectively managed procedural timelines to ensure a long discovery process"  and it's likely that an initial court decision won't happen until late 2023 with a final ruling in 2024.See SA contributor Avisol Capital Partners report from Dec. 15 entitled "Avadel's Xyrem Competitor: A Quick Overview" (AVDL)

For further details see:

Jazz Pharma starting to clear away legal overhang, Evercore ISI says